Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Zerun 9-valent HPV Vaccine in Chinese Females
NCT03900572Phase 1Completed
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Zerun 9-valent HPV vaccine in human papillomavirus infection (2 arms), sponsored by Shanghai Zerun Biotechnology Co., Ltd. Primary endpoints: Percentage of Subjects Reporting Solicited Local Symptoms, Percentage of Subjects Reporting Solicited General Symptoms and 2 more. Started Mar 2019; status: completed.
02
Drugs
Zerun 9-valent HPV vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03900572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900572.